INDEX

Note: The alphabets “e,” “f,” and “t” following a page number denotes the exhibit, figure and table, respectively on the referenced page.

Abbreviated New Drug Application (ANDA):
- FDA approval process, 272f
- FDA license application, 262–9
Abilify (aripiprazole):
- case study, 184
- top 10 best-selling products, 7t
- ab initio calculations, small molecule drug discovery, 77–8
Abraxane (paclitaxel), nanotechnology, 184
- absorption, distribution, metabolism, excretion (ADME):
- drug delivery systems, 181–3
- generic drug approval, 271
- in silico studies, 172–5
- Investigational New Drug (IND), 257
- microdosing, clinical trials, 197e
- PK, 158–69
- accelerated approvals/schemes:
  - EMA, 280
  - FDA, 236, 259–61
Accelerating Medicines Partnership, drug discovery, 37e
Access and Benefit-Sharing Agreement (ABA), drug discovery, 63e
- accuracy, analytical methods validation, 345e
Acquired Immunodeficiency Syndrome (AIDS):
- Retovir (zidovudine, AZT), vaccines, 94e, 115e
- third world, 441e
acronyms, table of, 509–18
activation energy (free energy), enzymatic reactions, 41e
active pharmaceutical ingredient (API):
- Compliance Program Guidance Manual, FDA, 375e
- finished dosage forms, 394–7
- manufacture, large molecule drug, 369–71, 385–94
- manufacture, small molecule drug, 369, 379–85

Drugs: From Discovery to Approval, Third Edition. Rick Ng.
© 2015 John Wiley & Sons, Inc. Published 2015 by John Wiley & Sons, Inc.

519
active pharmaceutical ingredient (API) (cont’d)
  packaging and labeling, 324, 397, 398e
  production, safety, 368
  regulatory requirements, PIC/S guide, 311,
  314e, 315e, 316e, 318
active transport, PK, 158, 160
adaptive clinical trial, 220–221
Adcetris (brentuximab vedotin), conjugate
antibodies, 123
adjuvant, vaccines, 112–14
adverse events:
  clinical trials, 210
  in US, history, 302e
affinity chromatography, large molecule drug
purification, 393e
Afrezza, inhalable insulin, 137e
aging, future research, 423, 427e
agonist, definition, 38
airborne environmental cleanliness
requirements, GMP, 320t
Alexander Fleming, penicillin, 93e, 455, 456e
allogeneic transplant, definition, 142e
allosteric binding, drug-target interactions,
39–40
Alprolix (Factor IX), regulatory approval,
269, 270e
alternative medicine, future research, 414,
417–18
Alzheimer’s disease:
  Accelerating Medicines Partnership, 37e
  future research, 423, 424e, 445–7
  Metformin, phase II clinical study, 198e,
  199e, 200e
  PK, 165e
  vaccines, 114e
  Ames test, toxicology, 172e
  amino acids, names and properties, 463, 467
  amyloid precursor protein (APP),
  Alzheimer’s disease, 446
analytical methods:
  drug manufacture, 373e
  GMP validation, 345–7
  NDA/BLA, 265
  angiotensin-converting enzyme (ACE)
  inhibitor, drug discovery, 64
animal studies:
  preclinical studies, 172–5
  repeated dose toxicity, 171
  transgenic technologies, 432–3
antagonist, definition, 38–9
anthrax, bioterrorism, 431e
antibodies:
  chimeric, 121
  conjugate, 123–4
  fully human, 121
  human immune system, 117e
  humanized, 121
  monoclonal (MAb), 121
  production, hybridoma, 122f
  production, recombinant methods, 385–94
  recent FDA approved MAbs, 125t, 126t,
  127t
  structures, 118–20, 123–4
  traditional, 120
antigen-binding fragment (Fab, Fab’, F(ab’)2),
antibody molecules, 119, 120f
antigen-presenting cell (APC), 117e, 118e
anti-inflammatory therapy, targets and
receptors, 53–7
antimicrobial drug resistance, 433–5
antitoxicity approach:
  drug discovery, 85, 87–8, 89e
  therapies, 90t
  approval letter, NDA/BLA, 269
  approval letter, NDA/BLA, 269
  a priori target identification, drug discovery,
  24
Arabian medicine, early drug discovery, 454
arachidonic acid, prostaglandin conversion,
53–6
Aranesp, case study, 186–7
area under curve (AUC), PK, 162–3
Aspirin (acetylsalicylic acid):
  anti-inflammatory therapy, 53–6
  mechanism of action, 39e
assay:
  bioluminescence, 52e
  Caco-2 cell, 173e
  cell-based, 66
  development, 52
  enzyme-based, 66
  enzyme linked immunosorbent assay
  (ELISA), 111e
  regulatory guidelines, 267
atomic spectroscopy, analytical methods, 373e
ATryn, large molecule drug manufacture,
370e, 433
Australia’s Therapeutic Goods
Administration (TGA):
approval processes, 287, 288f
clinical trial applications, 289f
fees and charges, 290e
regulatory authority, 241–2
autologous transplant, definition, 142e
Avastin (bevacizumab):
  formulation, 180e
  MAb, 18t, 134, 135e
top 10 best-selling biopharmaceuticals, 7t
avian influenza (H5N1), 110e
B cell:
  human immune system, 117e, 118e
  hybridoma techniques, 122f
Bcl-2, potential antisense drug, 89e
Betaseron, IFN-β, 128
Bexxar, conjugate antibody, 123, 124e
bioavailability, formulations and delivery systems, 182t
biochemical pathways and networks, 26–9, 32, 36, 81, 152
biodiversity prospecting, regulations, 63e
bioethics, moral issues, 440–442
bioinformatics, small molecule drug discovery, 72–5
biosimilars:
  case study, 405–7
  Inflectra, EMA approval, 238
  Remsima, EMA approval, 238
bioterrorism agents, categories, 433e
bipolar disorder, clinical trial design, 226
bspecific antibodies, structure and function, 123–4
blood-brain barrier (BBB), PK, 165e
blood clot, formation process, 19–20
bone marrow transplant, cell therapy, 142e
Botox, lifestyle drugs, 427, 428e
bovine spongiform encephalopathy (BSE),
  large molecule drug manufacture, 390e
buccal and sublingual administration, PK, 158, 159f
buckyballs, polymeric drug delivery, 182e
buildings and facilities:
  FDA guidelines, 265–7
  GMP, 319–22
Cabilly patents, antibody expression, 437–40
Canada’s Health Canada:
  approval process, 287, 290
  Therapeutic Products Directorate (TPD), 243
cancer:
  drugs, examples, 106t
  metabolic targets for therapy, 86t, 87t
  p53 protein, 30e, 43, 220e, 241e
  vaccines, 115e
capillary array electrophoresis (CAE):
  analytical methods, 373e
  DNA sequencing, 83e
capsules, finished dosage forms, 395–6
captopril, ACE inhibitor, 42
carcinogenicity, preclinical studies, 170
case report form, clinical trials, 208–9, 211e
Celebrex (celecoxib):
  COX-2 inhibitor, 43e, 53–6
  formulation, 177e
cell bank:
  FDA guidelines, 267
  large molecule drug manufacture, 389e
cell culture methods, large molecule drug manufacture, 392e
cell growth, stages, large molecule drug manufacture, 390f
cell lines:
  FDA guidelines, 267
  large molecule drug manufacture, 389e
cells:
  chromosomes, 459e
  classification and structure, 457–60
  cell viability, large molecule drug manufacture, 391e
Center for Biologics Evaluation and Research (CBER), FDA, 235
Center for Drug Evaluation and Research (CDER), FDA, 233–5
centralized authorization procedure, EU, 236–7, 276, 277f
cervical cancer, Gardasil, 111e
challenges, pharmaceutical companies, 445f
change controls, GMP, 333–4, 351
Chantix (varenicline), smoking cessation treatment, 428
chemical and biological terrorism, 428, 432
chemical formulas:
  FDA Form 356h, 265–7
  selected drugs, 64e
chemical reactions, small molecule drug manufacture, 382e
Chemistry, Manufacturing and Control (CMC), FDA guidelines, 257, 258t, 259t
cold chain, GMP, 397–8
clean-in-place (CIP), GMP, 337–8
clean-out-of-place (COP), GMP, 337–8
cleanrooms:
  biosafety levels, 321, 323e
  pressure differentials, 319–22
clinical data management, clinical trials, 215–18
clinical research organization (CRO), clinical trials, 212
Clinical Trial Certificate (CTC), Singapore, 206
clinical trial design, bipolar disorder, 226–7
Clinical Trial Exemption (CTX), UK, 204
clinical trial failures, 173e
Clinical Trial Notification (CTN), Australia, 206
clinical trials:
  adaptive, 220–221
  Australia, 287, 289f
  Canada, 287–8
  China, 240e, 282–4, 286f
clinical data management, 215–16
definition, 192
ethical considerations, 192–5
EU, 273–5
failures, 223e
Gardasil, case study, 222, 224–6
gene therapy, 218–20
India, 287
Japan, 280–281, 283f
meta-analysis, 221–2
phases:
  phase I, 195–6
  phase II, 197–8
  phase III, 200–204
  phase IV, 204
Plavix, case study, 222
reflections, 223
regulatory authorities, 218
regulatory requirements, 204–15
US, 254–62
cloning, moral issues, 420–422
class of differentiation (CD), immune system, 118e
Cochrane Collaboration, meta analysis, 221
Code of Federal Regulations (CFR):
  21 CFR, 236t, 265
  21 CFR Parts 50, 56 and 312, 207e
  21 CFR Parts 210, 211, 600 and 610, 303–7
cold chain, GMP, 397–8
combinatorial chemistry, small molecule drug discovery, 78–81
Committee for Medicinal Products for Human Use (CHMP), EU, 238
Committee for Medicinal Products for Veterinary Use (CVMP), EU, 238
Common Technical Document (CTD): clinicals, 267
CMC, 267
electronic (eCTD), 265
ICH guidelines, 245e
Module 1, 291
Module 2, 291–2
Module 3, 292–3
Module 4, 292, 294
Module 5, 292, 295
NDA/BLA, 239
nonclinical, 267
comparability studies:
biosimilars, 406
biotechnological/biological products, 310e
complaints and recalls, GMP, 334
computational chemistry, small molecule drug discovery, 75–8
counterfeit drugs, case study, 447–9
defiled persons, US legislation, 271
decentralized procedure, EMA, 238
Declaration of Helsinki, World Medical Association, 196e
Define-Measure-Analyze-Improve-Control (DMAIC) model, Six Sigma, 358–60
dendrimer structures, polymeric drug delivery systems, 182e
design of experiment (DOE), GMP, 343, 344e
design qualification (DQ), GMP, 327
design space, pharmaceutical development, 356e
deviations/discrepancies, GMP, 324, 330–331
dextropropoxyphene, chemical structures, 384e
diabetes:
old age, 425e
types I and II, 136e
diffusion, PK, 161e
dissolution test, formulations, 179e
distribution, PK, 164, 165e
DNA, classification and structure, 460–461, 462f
docking simulation, computational chemistry, 76–8, 79e
documentation and records, GMP, 322–3
Dolly the sheep, cloning and stem cells, 422e
dose-effect curves, PD, 156f
double-blinded clinical trials, guidelines, 209
Crixivan (indinavir), accelerated approval, 236
cross over design, clinical trials, 212e
Cubicin (daptomycin), antibiotics, 435
custom (bespoke) software, GMP, 343e
cyclooxygenase (COX) inhibitors:
case study, 54–6
enzyme inhibition, 43e
cystic fibrosis, gene mutation, 31e
cytokine:
P-450, PK, 165–6
cytokines:
interferons, 128, 129e, 130e
interleukins, 130–131
large molecule drug discovery, 128–34
tumor necrosis factor, 131, 132e
data mining, small molecule drug discovery, 72, 75
default, leading causes, 443t, 444t
debarred persons, US legislation, 271
decentralized procedure, EMA, 238
Declaration of Helsinki, World Medical Association, 196e
Define-Measure-Analyze-Improve-Control (DMAIC) model, Six Sigma, 358–60
dendrimer structures, polymeric drug delivery systems, 182e
design of experiment (DOE), GMP, 343, 344e
design qualification (DQ), GMP, 327
design space, pharmaceutical development, 356e
deviations/discrepancies, GMP, 324, 330–331
dextropropoxyphene, chemical structures, 384e
diabetes:
old age, 425e
types I and II, 136e
diffusion, PK, 161e
dissolution test, formulations, 179e
distribution, PK, 164, 165e
DNA, classification and structure, 460–461, 462f
docking simulation, computational chemistry, 76–8, 79e
documentation and records, GMP, 322–3
Dolly the sheep, cloning and stem cells, 422e
dose-effect curves, PD, 156f
double-blinded clinical trials, guidelines, 209
Crixivan (indinavir), accelerated approval, 236
cross over design, clinical trials, 212e
Cubicin (daptomycin), antibiotics, 435
custom (bespoke) software, GMP, 343e
cyclooxygenase (COX) inhibitors:
case study, 54–6
enzyme inhibition, 43e
cystic fibrosis, gene mutation, 31e
cytokine:
P-450, PK, 165–6
cytokines:
interferons, 128, 129e, 130e
interleukins, 130–131
large molecule drug discovery, 128–34
tumor necrosis factor, 131, 132e
data mining, small molecule drug discovery, 72, 75
default, leading causes, 443t, 444t
debarred persons, US legislation, 271
decentralized procedure, EMA, 238
Declaration of Helsinki, World Medical Association, 196e
Define-Measure-Analyze-Improve-Control (DMAIC) model, Six Sigma, 358–60
dendrimer structures, polymeric drug delivery systems, 182e
design of experiment (DOE), GMP, 343, 344e
design qualification (DQ), GMP, 327
design space, pharmaceutical development, 356e
deviations/discrepancies, GMP, 324, 330–331
dextropropoxyphene, chemical structures, 384e
diabetes:
old age, 425e
types I and II, 136e
diffusion, PK, 161e
dissolution test, formulations, 179e
distribution, PK, 164, 165e
DNA, classification and structure, 460–461, 462f
docking simulation, computational chemistry, 76–8, 79e
documentation and records, GMP, 322–3
Dolly the sheep, cloning and stem cells, 422e
dose-effect curves, PD, 156f
double-blinded clinical trials, guidelines, 209
drug:  
approval, FDA, 444f  
blockbuster, 6  
definition, 2e  
development process, 254, 255f  
discovery and development, history, 451–6  
GMP, 301–2  
drug delivery systems:  
nneedleless injection, 183e  
polymeric compounds, 182e  
drug discovery and development:  
antisense approach, 14, 85, 87–8, 89e  
assay development, 52  
biopharmaceuticals/biologics approach, 14, 103–46  
clinical stage, 4, 191–222  
cost, 5e  
discovery stage, 3–4, 61–94, 103–41  
economics, 11–13  
EU regulations, 272–80  
future challenges, 411–12  
gene therapy approach, 14, 137–9  
guidelines, NIH, 96–8  
history, 451–6  
irrational approach, 14, 62–7  
large molecule, 103–46  
lock and key analogy, 24  
manufacturing stage, 4, 301–52, 367–400  
marketing stage, 4  
mechanism of action, 48t, 469–80  
postapproval stage, 4–5  
preclinical stage, 4, 151–84  
process, 23–4, 25f  
rational approach, 14, 67–85  
RNA interference approach, 14, 88–91  
small molecule, 61–98  
stem cell approach, 15, 139–41  
target, number, 52–3, 54t  
US regulations, 254–73  
drug manufacture, large molecule:  
cell bank, 387, 389e  
cell growth, stages, 390f  
cell line, 389e  
end of production cell bank, 394  
mammalian cells, 387  
microbial cells, 386  
nutrient medium, 387, 389–92  
protein synthesis route, 369–70  
purification, 393e  
viability of cells, 391f  
viable cells, 391f  
yield, 392  
drug manufacture, small molecule:  
chemical reactions, selected, 382e  
chiral synthesis, 383–5  
organic chemistry synthesis route, 369, 379–85  
purification, 383  
reagents, 381  
Drug Master File (DMF), FDA, 267–8  
drug products, compliance and supply shortages, 400, 401–4  
drugs and target receptors, drug discovery, 47t  
drug stability, GMP, 179e, 349–50  
drug-target interactions, drug discovery, 37–40  
economic issues, drug discovery and development, 11–13  
Edward Jenner, small pox vaccine, 455e  
effectiveness, PD, 156  
Egyptian medicine, early drug discovery, 452  
 electrostatic forces, drug-target interactions, 39–40  
EMA’s positive opinion in year 2013, new drug approval, 292, 294, 297t, 298t  
Enbrel (etanercept):  
case study, 184–5  
formulation, 180e  
manufacture, recombinant technology, 394e  
rheumatoid arthritis, 132e  
top 10 best-selling biopharmaceuticals, 7t  
end of production cell bank (EPCB), large molecule drug manufacture, 394  
Environmental Protection Agency (EPA), 243  
enzyme linked immunosorbent assay (ELISA), vaccines, 111e  
enzymes:  
active site, 40  
catalyst, 41e, 379, 385  
cyclooxygenase, 54–6  
drug interactions, 36–40  
reactions, 41e  
etiophate, vaccines, 111e, 121  
Epogen:  
biosimilars, 406  
growth factors, 133  
mechanism of action, 472  
top 10 best-selling biopharmaceuticals, 7t  
ethical issues:  
bioethics, 440–442
clinical trials, 192–5
EU GMP guide part I, 308
EU GMP guide part II, 308, 318e
eukaryote cell, 457–60
European Drug Master File (EDMF), EMA, 278, 279e
European Medicines Agency (EMA):
  abridged national authorization procedure, 278
  accelerated assessment, 280
  application fees, 280t
  centralized procedure, 236–7
  clinical trial authorization (CTA), 274–5
  clinical trial notification (CTN), 273–4
  Committee for Medicinal Products for Human Use (CHMP), 238, 278
  Committee for Medicinal Products for Veterinary Use (CVMP), 238
decentralized procedure, 238
marketing authorization, 275–80
mutual recognition procedure, 237–8
risk-based approach, 352–8
European Public Assessment Report (EPAR), EMA, 278–9
European Union:
  Directive; clinical trials, 273
  Directive, drug approval authorization procedure, 236
  Directive, environment, 319
  Directive, GMP, 311
  Directive, microorganisms, 321
  Directive, pharmacovigilance, 238
  GMP regulations, 308–9
  inspection guidelines, 378t
excipients, formulations, 18, 94, 160, 175–81, 354, 368–70, 395–7
exclusion criteria, clinical trials, 208
excretion, PK, 166–8
expressed sequence tags, drug discovery, 32, 34
extraction process, small molecule drug discovery, 63–4
Exubera, inhalable insulin, 137e
facilitated diffusion, PK, 160
factorial design, clinical trials, 212e
factory acceptance test (FAT), GMP, 329
failure mode and effects analysis (FMEA), risk-based approach, 331, 357e
fair subject selection, clinical trials, 192–3
FDA Guidance for Industry:
  biosimilarity, 405–6
  Chemistry, Manufacturing and Control (CMC), 257, 259t
  comprehensive quality system, 351
dissolution test, 179e
electronic records, electronic signatures, 338
oversight of clinical investigations, 352
process validation, 326
safe starting dose, 174
sterile drug products, 352
FDA regulations/guidelines:
  21CFR, 236t
  21CFR Part 11, 338, 340e, 341e
  21CFR Part 210, 303, 303e
  21CFR Part 211, 303, 303e, 304e, 305e
  21CFR Part 212, 303, 303e
  21CFR Part 600, 306e
  21CFR Part 610, 303, 307e
FDA’s approved drugs in year 2013, 292, 294, 296
fetal bovine serum (FBS), large molecule drug manufacture, 387
finished dosage forms:
  inhalants, 397
  liquids, 396
  ointments and creams, 397
  packaging and labeling, 397
  parenterals, 396–7
  solids, 395–6
finished products:
  dosage forms, 394–7
  GMP, 324–6
firmware, GMP, 343e
fluorescence-activated cell sorter (FACS), vaccines, 111e
Food, Drug and Cosmetic Act (FDCA), 235
Food and Drug Administration (FDA):
  Biologics License Application (BLA), 234
  21CFR regulations, 236
  Center for Biologics Evaluation and Research (CBER), 235
  Center for Drug Evaluation and Research (CDER), 233–5
CMC guidelines, 257–9, 265–7
expedited programs, 259–62
Form 356h, license applications, 262, 264f
Form 483, inspection, 375
Form 484, inspection, 376
generics, 271, 272f
GMP initiative, 350–352
Food and Drug Administration (FDA)
(cont’d)
GMP regulations, 302–7
history, 234e
inspection guidelines, 375e
Investigational New Drug (IND), 234,
254–62
New Drug Application/Biologics License
Application (NDA/BLA), 234,
262–70
orphan drugs, 270
over-the-counter drugs, 271, 273f
Pathway to Global Product Safety and
Quality, report, 249–50
processes and controls, 235–50
review mechanism, 268–70
formulations and delivery systems:
delivery systems, 181–2
formulations, 175–81
lyophilization, 181e
fully human antibodies, antibodies, 121
Fuzeon (enfuvirtide), HIV fusion inhibitor, 369e
Gardasil:
clinical trial, 222, 224–6
HPV vaccine, 111e
gas sterilization, GMP, 348
gel filtration, large molecule drug purification, 393e
Genasense (oblimersen), antisense drug, 89e
gene chip, microarray, 32–5
Genentech, 437
generally recognized as safe (GRAS),
excipients, 178
generics:
case study, 404–5
EU approvals, 278
FDA approvals, 271
FDA rules, 440e
genes, basic properties, 462–4
genes and molecular complexity, human
genes, 27e
gene therapy:
clinical trials, 218–19
drug discovery, 14
FDA oversight, 436e
large molecule drug development, 137–9
research issues, 420
genetic biomarkers, personalized medicine, 421t
genetic codes, dictionary, 465e
genetic disorders, 466e
genetic variations, personalized medicine, 419e
genomics and proteomics, small molecule
drug discovery, 81
genotoxicity, preclinical studies 171
GlaxoSmithKline (GSK), 377e
Gleevec/Glivec (imatinib mesylate), tyrosine
kinase inhibitor, 82e, 237e
Glybera (alipogene tiparvovec), gene therapy, 139
Good Agricultural Practice (GAP),
traditional medicine development, 418
Good Automated Manufacturing Practice
(GAMP), computerized system, 341–2
Good Clinical Practice (GCP):
regulatory authorities, 231–2
regulatory guidelines, 204–15
Good Laboratory Practice (GLP):
animal studies, 172–5
clinical trials, 204–15
regulatory authorities, 231–2
regulatory guidelines, 153e
Good Manufacturing Practice (GMP):
analytical methods validation, 345–7
buildings and facilities, 319–22
change controls, 333–4
cleaning and cleaning validation, 337–8
complaints and recalls, 334
compliance problems, 400, 401–4
computer system validation (CSV), 338–42
core elements, 317–35
corrective and preventive action (CAPA), 330–331
deficiencies, 378t
documentation and records, 322–3
drug manufacture, 367–407
EU GMP guide part I, 308
EU GMP guide part II, 308
EU requirements, 308–9
FDA, 302–7
implementation, 371–2
inspections, 372, 375–9
laboratory controls, 324–6
large molecule, 385–94
<table>
<thead>
<tr>
<th>Index</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>materials management, 323–4</td>
<td></td>
</tr>
<tr>
<td>new initiatives, FDA, 350–352</td>
<td></td>
</tr>
<tr>
<td>packaging, identification and labeling, 324</td>
<td></td>
</tr>
<tr>
<td>personnel, 319</td>
<td></td>
</tr>
<tr>
<td>PIC/S, 311–18</td>
<td></td>
</tr>
<tr>
<td>process equipment, 322</td>
<td></td>
</tr>
<tr>
<td>production and in-process controls, 324</td>
<td></td>
</tr>
<tr>
<td>quality management, 318–19</td>
<td></td>
</tr>
<tr>
<td>regulatory guidelines, 301–52</td>
<td></td>
</tr>
<tr>
<td>self-inspection, 334–5</td>
<td></td>
</tr>
<tr>
<td>small molecule, 369, 379–85</td>
<td></td>
</tr>
<tr>
<td>stability evaluation, 349–50</td>
<td></td>
</tr>
<tr>
<td>sterilization processes, 347–9</td>
<td></td>
</tr>
<tr>
<td>US requirements, 302–7</td>
<td></td>
</tr>
<tr>
<td>validation, 326–30</td>
<td></td>
</tr>
<tr>
<td>water system, 335–7</td>
<td></td>
</tr>
<tr>
<td>G-protein coupled receptors (GPCRs), drug discovery, 44, 46, 49</td>
<td></td>
</tr>
<tr>
<td>granulocyte macrophage colony stimulating factor (GM-CSF), growth factors, 133–4</td>
<td></td>
</tr>
<tr>
<td>Greek medicine, early drug discovery, 453</td>
<td></td>
</tr>
<tr>
<td>growth factors:</td>
<td></td>
</tr>
<tr>
<td>colony stimulating growth factor, 133–4</td>
<td></td>
</tr>
<tr>
<td>erythropoietin (EPO), 132–3</td>
<td></td>
</tr>
<tr>
<td>vascular endothelial growth factor (VEGF), 134</td>
<td></td>
</tr>
<tr>
<td>half-life, PK, 167–8</td>
<td></td>
</tr>
<tr>
<td>health systems, selected countries, 506–7</td>
<td></td>
</tr>
<tr>
<td>heating, ventilation and air-conditioning (HVAC), GMP, 321, 330, 374</td>
<td></td>
</tr>
<tr>
<td>Hemacord, stem cell therapy, 422, 423e</td>
<td></td>
</tr>
<tr>
<td>hepatitis C, interferons, 128e, 129e, 130e</td>
<td></td>
</tr>
<tr>
<td>Herceptin (trastuzumab):</td>
<td></td>
</tr>
<tr>
<td>approval, 420</td>
<td></td>
</tr>
<tr>
<td>case study, 123, 144–6</td>
<td></td>
</tr>
<tr>
<td>humanized antibodies, 121</td>
<td></td>
</tr>
<tr>
<td>Kadcyla, conjugate antibody, 123</td>
<td></td>
</tr>
<tr>
<td>sales, 16</td>
<td></td>
</tr>
<tr>
<td>top 10 best-selling biopharmaceuticals, 7t</td>
<td></td>
</tr>
<tr>
<td>herpes zoster (shingles), vaccines, 116e</td>
<td></td>
</tr>
<tr>
<td>HER2 receptor:</td>
<td></td>
</tr>
<tr>
<td>Herceptin (trastuzumab), 123</td>
<td></td>
</tr>
<tr>
<td>Tykerb (lapatinib), 145–6</td>
<td></td>
</tr>
<tr>
<td>high density lipoprotein (HDL), cholesterol, 17–18</td>
<td></td>
</tr>
<tr>
<td>high efficiency particulate air (HEPA) filter, GMP, 321</td>
<td></td>
</tr>
<tr>
<td>high performance liquid chromatography (HPLC), GMP, 373e</td>
<td></td>
</tr>
<tr>
<td>high throughput screening (HTS), small molecule drug discovery, 65–7</td>
<td></td>
</tr>
<tr>
<td>HIV:</td>
<td></td>
</tr>
<tr>
<td>biosafety level, 323e</td>
<td></td>
</tr>
<tr>
<td>drugs, 44e, 46e</td>
<td></td>
</tr>
<tr>
<td>Fuzeon, 369e</td>
<td></td>
</tr>
<tr>
<td>human immune system, 118e</td>
<td></td>
</tr>
<tr>
<td>life cycle, 45e</td>
<td></td>
</tr>
<tr>
<td>protease, 468f</td>
<td></td>
</tr>
<tr>
<td>vaccines, 94e, 115e</td>
<td></td>
</tr>
<tr>
<td>HMG-CoA reductase, cholesterol, 18–19, 94–5</td>
<td></td>
</tr>
<tr>
<td>Hormones:</td>
<td></td>
</tr>
<tr>
<td>human growth hormone (hGH), 136–7</td>
<td></td>
</tr>
<tr>
<td>insulin, 134–5, 136e, 136f, 137e</td>
<td></td>
</tr>
<tr>
<td>horse antiserum, antibodies, 120f</td>
<td></td>
</tr>
<tr>
<td>human-caused particles, GMP, 320e</td>
<td></td>
</tr>
<tr>
<td>human deoxyhemoglobin, structure, 467</td>
<td></td>
</tr>
<tr>
<td>human donor antibodies, traditional antibodies, 120</td>
<td></td>
</tr>
<tr>
<td>human equivalent dose, toxicology, 176t</td>
<td></td>
</tr>
<tr>
<td>Human Fertilization and Embryology Authority (HFEA), 441</td>
<td></td>
</tr>
<tr>
<td>Human Genome Project, 27, 49, 72, 81, 466–8</td>
<td></td>
</tr>
<tr>
<td>human growth hormone (hGH), hormones, 136–7</td>
<td></td>
</tr>
<tr>
<td>human immune system, antibodies, 117e</td>
<td></td>
</tr>
<tr>
<td>humanized antibody, antibodies, 121</td>
<td></td>
</tr>
<tr>
<td>human papillomavirus (HPV), Gardasil, 22s, 111e, 224–7</td>
<td></td>
</tr>
<tr>
<td>human subjects, clinical trials, 192, 195</td>
<td></td>
</tr>
<tr>
<td>Humira (adalimumab):</td>
<td></td>
</tr>
<tr>
<td>fully human antibody, 123</td>
<td></td>
</tr>
<tr>
<td>top 10 best-selling biopharmaceuticals, 7t</td>
<td></td>
</tr>
<tr>
<td>treatment of RA and autoimmune diseases, 9e</td>
<td></td>
</tr>
<tr>
<td>hybridization probing, microarray, 33f, 34e</td>
<td></td>
</tr>
<tr>
<td>hybridoma, MAb manufacture, 122f</td>
<td></td>
</tr>
<tr>
<td>hydrogels, polymeric drug delivery, 182e</td>
<td></td>
</tr>
<tr>
<td>hydrogen bonding, drug-target interactions, 40</td>
<td></td>
</tr>
<tr>
<td>hydrophobic effects, large molecule drug purification, 393e</td>
<td></td>
</tr>
<tr>
<td>hypertension, old age, 424e</td>
<td></td>
</tr>
<tr>
<td>hypothesis testing, clinical trials, 213e, 214e, 215e</td>
<td></td>
</tr>
<tr>
<td>ibuprofen, anti-inflammatory therapy, 39e, 53–6</td>
<td></td>
</tr>
</tbody>
</table>
ICH quality guidelines, 309–10
identification of materials, GMP, 324
Imbruvica (ibrutinib):
  accelerated approval, FDA, 261, 262e
tyrosine kinase inhibitor, 415e, 416e
immunoglobulins, antibodies, 117–27
immunotherapeutics, antibodies, 416e, 417e
inclusion criteria, clinical trials, 192–3, 208
independent review board/independent ethics committee (IRB/IEC), clinical trials, 193
India’s Central Drugs and Standard Control Organization (CDSCO), 240–241, 287
Indian (Ayurvedic) medicine, early drug discovery, 452
Inflectra, MAb biosimilar, 238
influenza viruses:
avian, H5N1, 110e
vaccines, 108e, 109e
informed consent, clinical trials, 193, 194e
inhalants:
  manufacturing guidelines, 397
  PK, 163
in-process controls, GMP, 324
in silico methods:
  drug discovery, 29, 32, 68, 75–8
  preclinical studies, 172–5
inspections:
  abbreviated, 374
  full, 374
  GMP, 372, 375–9
  typical problems, 376–7
installation qualification (IQ):
  cleaning, 337–8
  computer validation, 338–42
  GMP, 327–30
installation qualification (IQ):
  insulin, hormones, 134–5, 136e, 136f, 137e
  intellectual property rights (IPRs), 437–40
interferons (IFNs):
  Betaseron, 128
cytokines, 128, 129e, 130e
PegIntron, 128, 129e
pegylated, 129e
interleukins, cytokines, 130–131
in vivo testing, 4, 25, 173, 197e
ion exchange chromatography, large molecule drug purification, 393e
irrational approach to drug discovery:
biodiversity prospecting, 63e
extraction, 63–4
high throughput screening, 65–7
lead compound generation, 65
lead compound optimization, 65
natural product collection, 62–3
Ishikawa (cause and effect, fishbone) diagram, root cause analysis, 331e, 332e, 333e
ISO 14644-1, guidelines, 319
isoelectric focusing, GMP, 373e
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA)/Ministry of Health, Labor and Welfare (MHLW), 238–40, 280–283
Kadcyla (trastuzumab emtansine):
case study, 145
conjugate antibodies, 123
International Conference on Harmonization (ICH), guidelines:
clinical study efficacy, 205t
major categories, 245e
medical dictionary, 216
quality, 309e, 310e, 352–8
safety studies, 170e
ventricular repolarization, 174e
International Health Regulations (IHR), WHO, 246–9
International Medicinal Products Anti-Counterfeiting Taskforce (IMPACT), WHO, 448–9
International Nonproprietary Name (INN), WHO, 2
international regulatory authorities, 244t
intracellular receptors, drug discovery, 31e, 38, 52
intramuscular administration, PK, 163
intravenous administration, PK, 163–4
Investigational New Drug (IND):
  expedited programs, 259–62
  process, 256f
  regulatory guidelines, 234–5
  review, 257, 259, 261–2
investigator’s brochure, clinical trials, 206, 208e
investigators, clinical trials, 206
International Conference on Harmonization (ICH), guidelines:
clinical study efficacy, 205t
major categories, 245e
medical dictionary, 216
quality, 309e, 310e, 352–8
safety studies, 170e
ventricular repolarization, 174e
International Health Regulations (IHR), WHO, 246–9
International Medicinal Products Anti-Counterfeiting Taskforce (IMPACT), WHO, 448–9
International Nonproprietary Name (INN), WHO, 2
international regulatory authorities, 244t
intracellular receptors, drug discovery, 31e, 38, 52
intramuscular administration, PK, 163
intravenous administration, PK, 163–4
Investigational New Drug (IND):
  expedited programs, 259–62
  process, 256f
  regulatory guidelines, 234–5
  review, 257, 259, 261–2
investigator’s brochure, clinical trials, 206, 208e
investigators, clinical trials, 206
in vivo testing, 4, 25, 173, 197e
ion exchange chromatography, large molecule drug purification, 393e
irrational approach to drug discovery:
biodiversity prospecting, 63e
extraction, 63–4
high throughput screening, 65–7
lead compound generation, 65
lead compound optimization, 65
natural product collection, 62–3
Ishikawa (cause and effect, fishbone) diagram, root cause analysis, 331e, 332e, 333e
ISO 14644-1, guidelines, 319
isoelectric focusing, GMP, 373e
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA)/Ministry of Health, Labor and Welfare (MHLW), 238–40, 280–283
Kadcyla (trastuzumab emtansine):
case study, 145
conjugate antibodies, 123
Kalydeco, personalized medicine, 420
kidneys, PK, 166–9
killed/inactivated vaccines, traditional vaccines, 107–8
knockin and knockout mice, drug discovery, 36e
Kynamro ( mipomersen sodium), familial hypercholesterolemia treatment, 87

Labeling:
FDA Form 356h, 265, 266t
GMP, 324
manufacturing guidelines, 397
laboratory controls:
GMP, 324–6
toxicity grading, 499–503
large molecule drug discovery:
antibodies, 117–27
biopharmaceuticals, 105e
cytokines, 128–34
gene therapy, 137–9
growth factors, 132–4
hormones, 134–7
stem cells and cell therapy, 139–41
vaccines, 105–17
large molecule drug manufacture:
cell bank, 389e
cell line, 389e
GMP, 369–70
mammalian cells, 387–94
microbial cells, 386
recombinant DNA techniques, 388e
technological development, 414
Latin square design, clinical trials, 212e
Lean Manufacturing, manufacturing quality practice, 360–362
lethal factor, anthrax, 431e
lifestyle drugs, future research, 423, 425, 427–8
ligand-gated ion channels, drug discovery, 49–50
limit of detection, analytical methods validation, 345–7
limit of quantitation, analytical methods validation, 345–7
limulus amebocyte lysate test ( LAL), analytical methods, 373e
linearity, analytical methods validation, 345–7
Lipinski Rule of 5, small molecule drug development, 76

Lipitor ( atorvastatin):
case study, 18–19, 94–6
chemical name, 2
formulation, 177e
sales, 12, 437
liquid dosage forms, manufacturing guidelines, 396
local government authorities, regulations, 243
low density lipoprotein (HDL), cholesterol, 17–8
Lucentis ( ranibizumab):
MAb, 17, 135e
manufacture, 386
top 10 best-selling biopharmaceuticals, 7t
VEGF, 134
lymphokines, cytokines, 128
lyophilization, large molecule formulations, 181e
Maci, tissue-engineered medicine, 238
macrophage colony stimulating factor (M-CSF), growth factors, 133–4
macular degeneration, antibodies, 135e
major histocompatibility complex (MHC), immune system, 117e
malaria, vaccines, 115e, 116e
mammalian cells, large molecule drug manufacture, 387
manufacturing variations, GMP, 399–400, 401e
marine bioprospecting, small molecule drug discovery, 413e
marketing applications:
EU, abridged national authorization procedure, 278
EU, centralized procedure, 276, 277f
EU, mutual recognition procedure, 276–7
EU, national authorization procedure, 277–8
US, ANDA, 271
US, NDA/BLA, 262–71
US, OTC, 271
marketing exclusivities, 437–40
mass spectroscopy, analytical methods, 373e
master cell bank (MCB), GMP, 387
materials management, GMP, 323–4
maximum allowable carryover (MAC/MACO), cleaning validation, 339e
maximum recommended starting dose (MRSD), clinical trials, 174
mechanism of action, selected drugs, 113t, 469–80
MedDRA terminologies, ICH, 216e, 217e, 218e
medical needs, drug discovery, 24–6
Medicines and Healthcare Products Regulatory Agency (MHRA), clinical trials, 204
meningococcal vaccine, vaccines, 143–4
metabolism, PK, 164–6
metabolomics, small molecule drug discovery, 82
methicillin-resistant Staphylococcus aureus (MRSA), antibiotics, 435
microarray, drug discovery, 32–5
microbial cells, large molecule drug manufacture, 386
microbial contamination, GMP, 321t
microdosing, clinical trials, 197e
Middle East Respiratory Syndrome (MERS), IHR, 246
Ministry of Health, Labor, and Welfare (MHLA), Japan, 239
Molecular Libraries Screening Center Network (MLSCN), 67
monitoring, clinical trials, 209–10
monoclonal antibodies (MAbs): Avastin (bevacizumab), 135e conjugate, 123–6 Herceptin (trastuzumab), 123 hybridoma, 122f Lucentis (ranibizumab), 135e TGN1412 clinical trial, 213e
Monte Carlo simulations, small molecule drug discovery, 78
multiple dose, PK, 169f
multipotent, stem cell therapy, 140
mutual recognition procedure, EU, 237–8, 276
nanotechnology, drug delivery systems, 183–4
national authorization procedure, EU, 277–8
natural product collection, small molecule drug discovery, 62–3, 412
needleless injection, drug delivery systems, 183e
neurotransmitters, small molecule drug discovery, 51e
New Drug Application (NDA):
approval times, 269t
chemistry, 265
clinical results, 267
Drug Master File (DMF), 267–8
general guidelines, 234
marketing application, 262–71
nonclinical pharmacology and toxicology, 267
review, 268
review outcome, 269
new molecular entities (NMEs), 104
Nexium:
chemical formula, 64e
top 10 best-selling products, 7t
Nimenrix, vaccines, 143
no observed adverse effect level (NOAEL), animal tests, 174–5
Novartis, 17
nuclear magnetic resonance (NMR) spectroscopy:
basic principles, 71–2, 73e
small molecule drug development, 74e
nucleic acids, classification and structures, 460–462
Occupational Safety and Health Administration (OSHA), 243
ointments, finished dosage forms, 397
old age diseases and aging, future research, 423, 424e, 425e, 427e
oligonucleotides, antisense therapy, 85, 87–8
Ontak (denileukin diftitox), T cell lymphoma, 131e
open reading frame (ORF), vaccines, 111e
operational qualification (OQ):
cleaning, 337–8
computer validation, 338–42
GMP, 327–30
oral administration:
bioavailability, 182t
PK, 160–163
Orlistat, obesity management, 427
orphan drugs:
EMA, 276, 280
FDA, 270–271
osteoporosis, future research, 425e
out of specifications (OOS), GMP, 324–5, 331
over-the-counter (OTC), FDA, 235, 273f
INDEX

packaging and labeling, GMP, 324, 397, 398e
parallel group techniques, clinical trials, 212e
parallel track, clinical trials, 255f, 261
parenteral drugs, GMP, 339, 396–7
Parkinson’s disease, future research, 425e
passive diffusion, PK, 158–60
patients, 13e, 437–40
Patent Term Restoration (PTR), 438
Pathway to Global Product Safety and Quality, FDA report, 249–50

PegIntron:
  formulation, 180e
  half life, 128, 129e
penicillin, history, 93e, 455, 456e
peptide vaccines, vaccines, 112
performance-enhancing drugs, 133e, 428, 429t, 430t, 431t
performance qualification (PQ):
  cleaning, 337–8
  computer validation, 338–42
  GMP, 327–30
Persian medicine, early drug discovery, 454
personalized medicine, future research, 419–20, 421t
personnel, GMP, 319
Pfizer, 16–17
pharmaceutical industry:
  global sales, 6t
  top 10 best-selling biopharmaceuticals, 7t
  top 10 best-selling products, 7t
  top 10 biopharmaceutical companies, 12t
  top 10 companies, 10t
Pharmaceutical Inspection Cooperation Scheme (PIC/S):
  mission and member states, 246
  PIC/S GMP Guide Part I, 311, 312e, 313e
  PIC/S GMP Guide Part II, 311, 314e, 315e, 316e, 318e
  PIC/S Guide to GMP, Annexes, 317e
pharmacodynamics (PD):
  dose-effect curves, 156f
  effectiveness, 156
  potency, 156
  preclinical studies, 154–6
  safety margin, 157
  therapeutic index, 156
pharmacogenomics:
  assays and models, 444
  bioinformatics, 75
  personalized medicine, 419
pharmacokinetics (PK):
  absorption, 160–64
  distribution, 164, 165e
  excretion, 166–8
  metabolism, 164–6
  preclinical studies, 158–68
  transport mechanism, 158–60, 161e
pharmacology review format, 489–94
pharmacopoeias, GMP, 309e, 325, 337t, 345, 372
pH levels, PK, 161e
phosphorylation, drug-target interaction, 51
placebo, clinical trials, 209
placental barrier, PK, 165e
plasma concentration, PK, 158–69
plasmid, large molecule drug manufacture, 388e
plasmid vector (DHFR), expression vector, 481–2
Plavix (clopidogrel):
  case study, 19–20
  clinical trials, 222
  sales, 13
  pluripotent, stem cell therapy, 140
  pneumococcal vaccine, vaccines, 141–3
  polio, clinical trials, 219e
  polyclonal antibodies, vaccines, 120–121
  polymeric compounds, drug delivery systems, 182e
postmarketing:
  phase IV clinical trials, 204
  safety, 239
  surveillance inspection, 239
  potency, PK, 156
  p53 protein, tumor suppressor, 30e
  Pradaxa (dabigatran), stroke management, 423, 426e
preapproval inspection (PAI), 268
precision, analytical methods validation, 345–7
preclinical (nonclinical) studies:
  animal tests, 172–5
  formulations and delivery systems, 175–83
  nanotechnology, 183–4
  pharmacodynamics (PD), 154–6
  pharmacokinetics (PK), 158–68
  requirements, 151–87
  toxicology, 168–72
Prescription Drug User Fee Act (PDUFA), 268, 271t
Prevnar 13, vaccines, 142–3
Prilosec:
   formulations, 177e
   legal battle, 437e
process analytical technology (PAT), GMP, 352
process capability index (Cp), Six Sigma, 358–9
process equipment, GMP, 314e, 322, 330
process validation (PV), GMP, 342–5
production and in-process controls, GMP, 324
production yield, GMP, 392
product quality review, GMP, 398–9
prokaryote cell, 457
Proleukin, cytokines, 131e
Propecia (finasteride), hair baldness treatment, 428
propranolol, chemical structures, 384e
prostaglandin, arachidonic acid conversion, 53–7
proteins:
   extraction and studies, 84e
   manufacture, 369–71, 385–94
   properties and structures, 462–6
proteomics:
   Human Genome Project, 466–8
   protocol, clinical trials, 208, 210e
   proton pump inhibitor, acid reflux therapy, 92e
Provenge, stem cell therapy, 143e, 416e
Prozac (fluoxetine):
   chemical formula, 64e
   formulations, 177e
   sales, 437
Public Health Service Act (PHSA), 235
purification techniques:
   large molecule drug manufacture, 393e
   small molecule drug manufacture, 383e
   purified water (PW), GMP, 335–7
Quality:
   compliance problems and supply shortages, 400, 402–4
   CTD, 290–295
   FDA Pathway to Global Product Safety and Quality, report, 249–50
   GMP, 318–50
   ICH guidelines, 245
ICH quality documents, risk-based approach, 352–8
IND, 257
inspection, 372–9
manufacturing deficiencies, 378t
manufacturing variations, 399–400, 401e
NDA/BLA, 262
PIC/S, 246, 312–17
preclinical studies, 152–3
product quality review, 398
quality by design (QbD), FDA initiatives, 351
quality management system (QMS), 239
Six Sigma and Lean Manufacturing, 358–62
quantitative polymerase chain reaction (QPCR), 373e
racemic mixtures, small molecule drug manufacture, 91
radiation sterilization, GMP, 347
radioligand binding, drug discovery, 32e
randomization, clinical trials, 209, 212e
rapporteur, EMA, 278
rational approach to drug discovery:
   bioinformatics, 72, 75
   combinatorial chemistry, 78–81
   computational chemistry, 75–8
   genomics and proteomics, 81
   metabolomics, 82–3
   nuclear magnetic resonance (NMR), 71–2, 73e, 74e
   systems biology, 85, 88e
X-ray crystallography, 68–71
raw materials, GMP, 358t, 368, 371–2, 379–82
reagents, small molecule drug manufacture, 381
receptors:
   agonist, 38
   antagonist, 38–9
   cell surface, 37
   G-protein coupled receptors, 43–4, 46, 49–50
   intracellular, 36–7, 51
   ion-channel, 46, 49–50
   signal transduction, 42–4, 46, 49–51
   tyrosine kinases, 50–51
recombinant DNA (rDNA) techniques, GMP, 388e
records management, GMP, 322–3
regulatory authorities:
  Central Drugs and Standard Control Organization (CDSCO), 240–241
  China Food and Drug Administration (CFDA), 240
  European Medicines Agency (EMA), 236–8
  Food and Drug Administration (FDA), 223–6
  Pharmaceuticals and Medical Devices Agency (PMDA), 238–40
  roles, 218, 231–50
  selected international regulatory authorities, 244t
  Therapeutic Products Directorate (TPD), 243
  Therapeutics Goods Administration (TGA), 241–3
  regulatory issues, 435–6
  regulatory requirements, clinical trials:
    clinical research organization, 212
    ICH guidelines, 204, 205t, 207e
    inclusion and exclusion criteria, 208
    informed consent, 193, 194e
    investigator, 206
    investigator’s brochure, 206
    monitoring, 209–10
    protocol, 208, 210e
    randomization, placebo-controlled, double-blind, 209
    sponsor, 211
    statistics, 210–211, 213e, 214e, 215e
    surrogate markers, 212
    US 21CFR Parts 50, 56 and 312, 204, 207e
  regulatory requirements, GMP:
    EU, GMP guides parts I and II, 308–9
    ICH quality guidelines, 309–11
    PIC/S, GMP guides parts I, II and annexes, 311–17
    US, 21 CFR Parts, 210, 211, 600 and 610, 303–7
  regulatory requirements, preclinical studies:
    animal dose to human dose, 176t
    animal tests and assays, 172–5
    dissolution and stability tests, 179e
    formulations, 175–83
    GLP, 151–4
    ICH guidelines, 170e
    PD studies, 154–7
    PK studies, 158–68
  potential for delayed ventricular repolarization, 174e
  toxicity, 168–72
  Relenza (zanamivir), development, 71e
  Remicade (infliximab):
    TNF blocker, 132e
    top 10 best-selling products, 7t
  Remsima, monoclonal antibody biosimilar, 238
  Renaissance period, early drug discovery, 454
  repeatability, analytical methods validation, 345–7
  repeated dose toxicity studies, preclinical studies, 169–71
  reproductive toxicity, preclinical studies, 172
  research and development, statistics, 9–11
  reversed phase chromatography, large molecule drug purification, 393e
  reverse transcriptase, HIV drug development, 44e, 45e
  risk-based approach, GMP, 350–358
  risk-benefit ratio, clinical trials, 193
  RNA, classification and structure, 461
  RNA interference approach, small molecule drug discovery, 88–91
  robustness, analytical methods validation, 345–7
  Roche, 15–16
  Roman medicine, early drug discovery, 453
  root cause analysis, GMP, 331e, 332e, 333e
  Ruconest, transgenic protein, 434e
  ruggedness, analytical methods validation, 345–7
  safety studies:
    GMP, 320
    ICH guidelines, 170e
    PD, 156–7
    toxicology, 169–72
    sarin, bioterrorism, 431e
    Schering-Plough, 377e
    SCID, bubble boy syndrome, gene therapy, 139e
  scientific validity, clinical trials, 192
  scintillation proximity assay (SPA), small molecule drug discovery, 67
  screening of compounds, small molecule drug discovery, 65
  self-inspection, GMP, 334–5
Seretide/Advair:
  chemical formula, 64e
top 10 drugs, 7t
treatment of asthma and COPD, 8e
serum tumor markers, clinical trials, 215t
Severe Acute Respiratory Syndrome (SARS),
  IHR, 246–7
sickle cell anemia, gene targeting, 31e
signal transduction:
  drug development, 42–51
PD, 155
single nucleotide polymorphism (SNP), drug
discovery, 75, 419e
Six Sigma, GMP, 358–60
DMAIC model, 359–60
  process capability index (Cp), 358–9
six-system inspection model, GMP, 351
sleeping sickness, Africa, 441e
small molecule drug discovery:
  antisense approach, 85–8
  chiral drugs, 91–2
  irrational approach, 62–7
  rational approach, 67–85
  RNA interference approach, 88–91
small molecule drug manufacture:
  chiral synthesis techniques, 383–5
  conventional synthesis techniques, 379–83
  GMP, 371–2
smallpox, vaccines, 116e, 454, 455e
social value, clinical trials, 190
sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE),
analytical methods, 373e
software categories, GMP, 343e
solid dosage forms, GMP, 395–6
Soliris, antibodies, 280, 281e
Sovaldi (sofosbuvir), hepatitis C treatment,
  129, 261e
specificity, analytical methods validation,
  345–7
specific pathogen-free (SPF) conditions,
  preclinical studies, 172
sponsor, clinical trials, 211
sports medicine, performance-enhancing
drugs, 133e, 428–31
stability tests:
  formulations, 179e
  GMP, 349–50
standard safety margin (SSM), PD, 157
statistics, clinical trials, 210–211, 213e, 214e,
  215e
steam sterilization, GMP, 347–9
stem cell therapy:
  adult stem cell, 422
drug discovery, 15
human pluripotent stem cell, 422
induced pluripotent stem cell, 422
multipotent, 139–41
pluripotent, 139–41
totipotent, 139–41
sterilization processes:
  dry heat, 347
  D value, 348–9
  ethylene oxide, 348
  filtration, 348
  F value, 348–9
  radiation, 346
  Z value, 348–9
stroke, future research, 424e
structure activity relationship (SAR), small
molecule drug discovery, 75–6
subcutaneous administration, PK, 158–60
subunit vaccine, vaccines, 110, 111e
summary of product characteristics (SmPC),
  EMA, 274, 277–8
Supplementary Protection Certificate (SPC),
  438–9
surrogate markers, clinical trials, 212–13
Synercid IV (dalfopristin), accelerated
  approval, FDA, 435
tablets, finished dosage forms, 395–6
Tamiflu (oseltamivir):
  chemical formula, 64e
  development, 71e
target, orphan, 32e
target identification:
  expressed sequence tags, 32, 34
genes and biochemical pathways, 26–9
  microarray, 32, 33e, 34e, 35e
  radioligand binding, 29, 32
target validation, drug discovery, 33, 34
Taxol (paclitaxel), synthesis, 66e, 383e
  T cell, immune system, 117e, 118e
tetracycline, antibiotics, 64
TGN1412 MAb, clinical trials, 213e
Thalidomide, chemical structures, 384e
The Protein Data Bank, 69
therapeutic index, PD, 156
topical administration, PK, 163
totipotent, stem cell therapy, 140
toxicity, drug, 169–71
toxicology:
carcinogenicity, 170
genotoxicity, 171
in silico, 175e
nonrodents, 171
preclinical studies, 167–72, 489–94
reproductive toxicology, 172
rodents, 171
toxoids, vaccines, 109
Traditional Chinese Medicine (TCM), 240
traditional medicines, 62e, 414, 417–18
traditional medicine strategy, WHO, 418e
transcription, genetic information, 464
transdermal administration, PK, 163
transgenic animals and plants, future research, 432–3
translation, genetic information, 465
transport mechanism, PK, 158–60
Tretinoin, wrinkle treatment, 427
Tyrkerb (lapatinib), kinase inhibitor, 145–6
tyrosine kinase receptors, small molecule drug
discovery, 50–51
ultra-high throughput screening (UHTS),
small molecule drug discovery,
65–7
user requirement specifications (URS),
computer validation, 327–8, 341–3
Vaccae, clinical study, 202e, 203e
Vaccines:
adjuvant, 112–14
antibodies, 117–27
approved by FDA, 485–7
attenuated, 107
conjugate, 112
DNA, 112
drug discovery, 105–16
killed, inactivated, 107–9
peptide, 112
production methods, 484
research and clinical activities, 114
subunit, 110, 111e
toxoid, 109
vector-based, 112
validation:
analytical methods, 345–7
cleaning, 337–8
DQ, 327, 328e, 329–30
GMP, 326–30
IQ, 327, 328e, 329e, 330, 342
OQ, 328, 329e, 330, 342
PQ, 328, 329e, 330, 342
process validation, 327t, 342–5
URS, 327, 341
Validation Master Plan (VMP), 326–7
Validation Master Plan (VMP), GMP, 326–8
validation protocols, GMP, 330
vancomycin resistant Enterococcus faecium (VSE), antibiotics, 435
van der Waals forces, drug-target interaction, 40
variable fragment (Fv), antibodies, 119
vascular endothelial growth factor (VEGF):
Avastin (bevacizumab), 235e
growth factors, 134, 135e
Lucentis (ranibizumab), 135e
vector, gene therapy, 138t
ventricular repolarization and rapid irregular
heartbeat, ICH, 174e
vericella zoster virus (VZV), vaccines, 116e
viable cell concentration, large molecule drug
manufacture, 391f
Viagra (sildenafil), sexual dysfunction
treatment, 93e, 428
Vioxx (refecoxib), anti-inflammatory
treatment, 53–7
virtual screening, small molecule drug
discovery, 76–9
Vitrane (fomivirsen), antisense
development technique, 87
voltage-gated ion channel, drug development, 49–50
volume distribution, PK, 164
water-for-injection (WFI), GMP, 335–8
water system:
GMP, 335–7
purified water (PW), 335–7
water–for–injection (WFI), 335–7
working cell bank (WCB), large molecule
drug manufacture, 387
World Anti-Doping Association (WADA), 428
World Health Organization (WHO):
  influenza monitoring activities, 109e
  International Health Regulations (IHR), 246–9
  mission, 245–6
World Medical Association, Declaration of Helsinki, clinical trials, 195, 196e
World Trade Organization (WTO), 240

Xenical (orlistat), obesity management, 43e
Xolair (omalizumab), manufacture, mammalian cells, 387
X-ray crystallography, drug discovery, 68–71

Yervoy, immunotherapeutics, 416e
Zelboraf, immunotherapeutics, 416e
Zevalin, antibodies, 123, 124e
Zontivity (vorapaxar), heart attack and stroke management, 423, 426e, 427e
Zyban (bupropion), smoking cessation drug, 428
Zyprexa (olanzapine), case study, 185–6
Zytiga, immunotherapeutics, 416e
Zyvox (linezolid), antibiotics, 435